JW Pharmaceutical announced on the 26th that clinical results and real-world prescription experiences of fostamatinib (product name Tavlesse), a treatment component for immune thrombocytopenia (ITP), were shared at the Asia Bone Marrow Failure Syndrome Symposium (ABFS 2026) held from the 16th to the 17th at the Grand Walkerhill Seoul.


Tavlesse is an innovative first-in-class drug that inhibits spleen tyrosine kinase (Syk), a signal transduction protein involved in the body's immune response, thereby blocking the destruction of platelets. It was developed by the US pharmaceutical company Rigel Pharmaceuticals and received FDA approval in the United States in 2018. In the same year, Kissei Pharmaceutical in Japan secured the development and commercialization rights from Rigel Pharmaceuticals, and JW Pharmaceutical entered into a license-in agreement with Kissei Pharmaceutical in 2021 for domestic development and sales rights.

From the 16th to the 17th, at the Grand Walkerhill Seoul, the "Asia Bone Marrow Failure Syndrome Symposium (ABFS 2026)" was held, where clinical results and real-world prescription experiences of fostamatinib (brand name Tavalis), a treatment component for immune thrombocytopenia (ITP), were shared. Professor Masataka Kuwana from the Graduate School of Medical Sciences at Nihon University School of Medicine in Japan presented on the pathophysiological mechanisms of ITP, the results of the Japanese Phase 3 clinical trial of fostamatinib, and post-marketing surveillance (PMS) data. JW Pharmaceutical

From the 16th to the 17th, at the Grand Walkerhill Seoul, the "Asia Bone Marrow Failure Syndrome Symposium (ABFS 2026)" was held, where clinical results and real-world prescription experiences of fostamatinib (brand name Tavalis), a treatment component for immune thrombocytopenia (ITP), were shared. Professor Masataka Kuwana from the Graduate School of Medical Sciences at Nihon University School of Medicine in Japan presented on the pathophysiological mechanisms of ITP, the results of the Japanese Phase 3 clinical trial of fostamatinib, and post-marketing surveillance (PMS) data. JW Pharmaceutical

View original image

In a regular ITP session at ABFS 2026, Professor Masataka Kuwana from the Graduate School of Medical Sciences at Nihon University School of Medicine in Japan presented on the pathophysiological mechanisms of ITP, the results of the Japanese Phase 3 clinical trial of fostamatinib, and post-marketing surveillance (PMS) data.


Immune thrombocytopenia is an autoimmune disease in which the immune system targets and attacks platelets, causing platelet counts to fall below the normal range. When Fc gamma (γ) receptors, which activate or suppress immune responses, are activated, immune cells respond via Syk, leading to the development of ITP. This condition can cause easy bruising or bleeding, and in severe cases, may result in cerebral or gastrointestinal hemorrhage.


Professor Kuwana explained, "Unlike existing treatments that mainly promote platelet production, fostamatinib blocks the pathway of platelet destruction by inhibiting Syk involved in macrophage signal transduction. It also has a unique mechanism of action that may affect the signaling for autoantibody production by B cells, a type of immune cell."


According to the results of a Phase 3 clinical trial conducted on 34 Japanese patients, the 'stable platelet response rate' was 0% in the placebo group, while it was 36% in the fostamatinib group. In addition, among patients who responded to the treatment, platelet counts tended to rise above 50,000/μL within the initial two weeks of administration, and some cases maintained stable levels for over a year.


Professor Kuwana also shared interim analysis results from a large-scale Japanese post-marketing surveillance (PMS) study reflecting prescription data from over 600 patients in real clinical settings. The interim analysis indicated that no serious adverse events such as thromboembolism were reported, even among elderly patients and those with various comorbidities. Furthermore, the safety profile was reported to be similar when used in combination with existing TPO receptor agonists.


Concluding his lecture, Professor Kuwana emphasized the need for personalized ITP treatment. He stated, "Currently in Japan, research is underway to predict patient groups likely to respond to fostamatinib using specific biomarkers such as reticulated platelets. As research accumulates, it will help select the most appropriate treatment option between TPO receptor agonists and fostamatinib for each patient in the future."


JW Pharmaceutical plans to continuously work to improve access to information on Tavlesse in clinical settings and to expand evidence-based discussions on ITP treatment strategies.



A JW Pharmaceutical representative said, "The Japanese clinical and real-world prescription data shared in the official session of the symposium can provide evidence to inform ITP patient treatment strategies. We will strive to enhance information accessibility in clinical settings and to expand evidence-based discussions on patient treatment options."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing